/주식/GNFT
GNFT

GNFT

USD

GENFIT S.A. American Depositary Shares

$3.672-0.202 (-5.209%)

실시간 가격

Healthcare
생명공학
프랑스

가격 차트

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$3.874

고가

$3.874

저가

$3.672

거래량

0.00M

기업 기본 정보

시가총액

183.9M

산업

생명공학

국가

France

거래 통계

평균 거래량

0.01M

거래소

NMS

통화

USD

52주 범위

저가 $2.55현재가 $3.672고가 $6.423

AI 분석 리포트

마지막 업데이트: 2025년 4월 21일
AI 생성데이터 소스: Yahoo Finance, Bloomberg, SEC

[GNFT: GENFIT S.A. American Depositary Shares]: Is This Biotech Stock Ready to Turn Around?

Stock Symbol: GNFT Generate Date: 2025-04-21 06:24:16

Alright, let's take a look at GENFIT (GNFT), a biotech company focused on liver diseases. We've got some interesting signals here, so let's break it down without the financial mumbo jumbo.

Recent News Buzz: A Thumbs Up from the Analysts

So, what's the chatter around GENFIT lately? Well, we got a note from HC Wainwright & Co., a firm that follows these kinds of stocks. They're saying "Buy" and sticking to their $13 price target. Basically, at least one expert out there thinks this stock is a good deal and has room to climb significantly from where it is now. That's definitely a positive vibe in the news department. It's like getting a good recommendation from someone who knows the industry.

Price Check: A Bit of a Rollercoaster Lately

Now, let's peek at the stock price itself over the last month or so. If you look at the numbers, it's been a bit of a bumpy ride. Starting back in late January, we saw the price hovering around $3.60-$4.00. Then, as we moved into February and March, it generally drifted downwards, hitting lows in the $3.30-$3.40 range in early April. However, in the last few days before today, it seems to have stabilized, maybe even showing a tiny bounce back to around $3.50-$3.60.

Right now, the last closing price was around $3.575. So, we're sitting near the lower end of its recent range, and definitely below that $13 price target the analyst mentioned.

Interestingly, AI predictions seem to agree with the positive analyst sentiment. They're flagging this stock as potentially "undervalued" with "explosive growth" potential. They even suggest a possible entry point around $3.50-$3.63, which is right where the stock is currently trading. Their take-profit target is around $3.81, a bit higher than where we are now.

Outlook & Strategy Ideas: Is it Time to Consider GENFIT?

Putting it all together, what are we looking at? We've got positive news from an analyst, AI predictions hinting at upside, and a stock price that's been trending down recently but seems to be finding a floor.

Here's the potential leaning: This could be an interesting moment to consider GENFIT if you're looking for a potential turnaround play. The recent price dip, combined with the positive analyst view and AI's "undervalued" tag, might suggest a possible buying opportunity.

Potential Entry Consideration: If you're intrigued, watching for a move around the current price of $3.57 or even a slight dip towards $3.50 could be something to think about. This area seems to be acting as recent support, and it aligns with the AI's suggested entry zone.

Potential Exit/Stop-Loss Consideration: To manage risk, a stop-loss around $3.16 (as suggested by the AI data) could be a smart move. This would help limit potential losses if the stock price decides to keep falling. On the upside, a potential take-profit target around $3.81, again from the AI data, could be a first goal if the stock starts to move up. Remember, these are just potential levels to consider for risk management.

Company Context - Quick Reminder: GENFIT is in the biotech sector, specifically working on treatments for liver and metabolic diseases. They're in late-stage development, which means they're closer to potentially bringing products to market. Positive news on their drug development pipeline would likely be a big driver for the stock.

In short: GENFIT looks like it could be at an interesting point. Positive analyst sentiment and AI predictions are bumping up against recent price weakness. It's definitely not a guaranteed win, but for investors who understand biotech and are comfortable with some risk, it might be worth a closer look. Keep an eye on news around the company and how the stock price behaves around these levels.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. I am providing an interpretation of publicly available stock information. Investing in the stock market involves risk, and you could lose money. Always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

관련 뉴스

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Genfit, Maintains $13 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates Genfit with a Buy and maintains $13 price target.

더 보기
HC Wainwright & Co. Reiterates Buy on Genfit, Maintains $13 Price Target

AI 예측Beta

AI 추천

중립

업데이트 시간: 2025년 4월 28일 오후 05:47

약세중립강세

58.2% 신뢰도

리스크 & 트레이딩

리스크 수준4/5
고위험
적합 대상
공격적가치
트레이딩 가이드

진입점

$3.68

익절

$4.01

손절

$3.28

핵심 요소

현재 가격은 $3.74에서 MA(20)보다 2.7% 낮아 하락 모멘텀을 나타냅니다.
DMI는 약세 추세(ADX:11.6, +DI:36.5, -DI:41.1)를 보여 주의를 요합니다.
현재 가격이 지지선($3.72)에 매우 근접하여 강력한 매수 기회를 시사합니다.
MACD 0.0315이(가) 신호선 0.0452 아래에 있어 약세 교차를 나타냅니다.

최신 정보 받기

가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기